NasdaqGM · Biotechnology

Candel Therapeutics (CADL)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+59.9%

$21.00 average target

$13.13+0.78 (+6.3%)Latest market snapshot · Yahoo Finance

Market cap$1.00B

Cash$201.6M

Quarterly burn$18.0M

Pipeline assets6

Short float22.5%

Latest coverage

News & Press Releases

External sources

Aug 21, 2026

Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed?Simply Wall St.

Aug 20, 2026

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks PriceySimply Wall St.

Aug 14, 2026

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9MT Newswires

Continue with BioPharma ProUnlock 4 more recent stories and press releases.

Unlock Pro

Company profile

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.